Adewuyi, B. T., and *,3Adewuyi, G. M.
1Department of Family Medicine, Irrua Specialist Teaching Hospital, Edo State, Nigeria
2Department of Medical Microbiology & Parasitology, Irrua Specialist Teaching Hospital, Edo State, Nigeria 3Department of Medical Microbiology & Parasitology, Ambrose Alli University, Ekpoma, Edo State, Nigeria
*Correspondence to: email@example.com
Background: With the use of highly active antiretroviral therapy (HAART), life expectancy of HIV-infected persons had increased and the disease is now managed as a chronic one, but the quality of life (QOL) of the patients is now a concern. Social support enhances QOL of patients with chronic illnesses. However, no study has been done to determine the QOL of people living with HIV and AIDS (PLWHA) in our environment. This study therefore assessed the QOL of PLWHA attending antiretroviral therapy (ART) clinic of Irrua Specialist Teaching Hospital (ISTH), Edo State of Nigeria
Methodology: A descriptive cross-sectional study design was used. Two hundred and thirty PLWHA attending the ART clinic of ISTH, Irrua, Edo State, Nigeria, were systematically selected for the study. A structured questionnaire was interviewer-administered to collect data on sociodemographic and clinical profiles of selected participants, and the WHOQOL-HIV BREF questionnaire was used to collect data the QOL of each participant. Data were analyzed with IBM SPSS version 20.0. Continue reading “Quality of life of people living with HIV and AIDS attending Irrua Specialist Teaching Hospital, Edo State, Nigeria”
V.U. Nwadike, C.G. Anaedobe, R.A. Azeez, S.S. Jinadu, J.O. Chigozie
Herpes Simplex Virus type 2 (HSV-2) is the leading cause of Genital Ulcer Disease (GUD) worldwide. In HIV infected persons, it typically presents with increased number of recurrent genital lesions which often have severe and prolonged presentations. There are reports that patients receiving highly active antiretroviral therapy (HAART) may be more prone to chronic genital ulcers and a higher risk of acyclovir-resistant herpes infection than is seen in immune competent patients. We present a case of recurrent genital herpes infection in a sexually active 15 year old known HIV patient.
Keywords: Recurrent genital ulcer, HSV-2, HIV, HAART
Download full journal in PDF below
Atypical presentation of genital herpes in a retroviral disease patient on highly active anti-retroviral therapy
O.J. Alabi, S.P.O. Akogu, M Akpa, V Ukeje, P.O. Okpanachi, O.G. Agama, S Gideon, B Adegboro
Examination of haematological profile is useful for baseline assessment, treatment monitoring and prognostic evaluation in Hiv/AIDS management. The objectives of the study was to assess the haematological profile of HIV seropositive HAART naive patients who attended Kogi State University Teaching Hospital, Anyigba, Kogi State, Nigeria between January 1, 2014 and December 31, 2014. The study was prospective experimental research. Ethical clearance was obtained from ethical committee of Kogi State University Teaching Hospital, Anyigba. Written and verbal informed consent was taken from all patients. A total of 404 HIV seropositive HAART naive patients comprising 147 (36.4%) males and 257(63.6%)females were examined. The overall mean age of patients was 33.0 ±12.7 years and female-male ratio was 1.7: 1. Half of respondents 200(50.4%) accessed HIV care and treatment for the time in stage three HIV disease. Patients had overall mean CD4 cells count of 381.8 ± 240.8 cells/mm3 , white blood cells count of 5.8 ± 3.6 × 109/L, lymphocyte count 2.3 ±1.3, granulocyte count 0.8 ± 0.8 and platelet count of 260.0 ± 109.1 × 109/L. The mean packed cell volume was 34.1± 5.9 %, haemoglobin 11.3 ± 2.1 g/dl and mean corpuscular haemoglobin concentration was 31.5 ± 14.3 g/dl. The packed cells volume (p=0.0001, T test= 4.0259) and haemoglobin (p=0.0001, T test= 4.1534) profiles of HIV clients were respectively statistically significance with gender, while CD4 cells count ( p=0.004, F= 4.523) and platelet count (p= 0.008, F = 3.974) were significance respectively with HIV disease staging. The study recommended the need for awareness programs, nutritional education and micronutrients supplementation including multivitamins for HIV clients.
Keywords: Haematological, HIV, HAART, patients, KSUTH, Nigeria
Download full journal in PDF below
Haematological profile of HIV seropositive HAART naive clients in Kogi State University Teaching Hospital, Anyigba, Kogi State. Nigeria
NN Odunukwe, JO Okwuzu, AP Okwuraiwe, TA Gbajabiamila, ZA Musa, PM Ezeobi, EO Somefun, OO Kalejaiye, DI Onwujekwe, OB Salu, CK Onwuamah, RA Audu, OC Ezechi
Objective: Management of viral hepatitis in patients with HIV disease is quite challenging and complex. With effective HIV treatment, people with HIV/HBV co-infection are living longer. HBV epidemiologic surveys showed an inverse association between selenium (Se) level and regional cancer incidence, as well as viral infection. This study assessed effect of selenium as adjunct to HAART in management of HIV/HBV co-infection.
Methods: A randomized open label study with participants allocated into three treatment groups: – HAART-only, Se-only and HAART-plus-Se. HIV viral load, HBV viral load, CD4 cell count, and alanine aminotransaminase (ALT), were analyzed at baseline and 18th month, analyzed using SPSS 5 v11. Ethical approval was obtained from Institute’s Ethical Review Board.
Results: Sample size was 149 HIV/HBV patients. Rate of HBV clearance was higher among those on HAART-plus-Se at 18th month when compared with rate of clearance among those on HAART-only (p=0.046). CD4 count increment among HAARTplus- Se group compared with HAART-only group was higher (p=0.133), though not statistically significant. On comparison of baseline and 18th month ALT, there was significant decline for HAART-plus-Se (p=0.002) compared with HAART-only group.
Conclusion: Selenium seems to have protective effect on liver cells; may be beneficial as adjunct to HAART in HIV/HBV management.
Key words: HIV/HBV co-infection, Selenium adjunct, HAART
Download full journal in PDF below
Selenium as adjunct to HAART in the management of HIVHepatitis B Virus coinfection A Randomized open label study
AK Salami, PO Olatunji, EA Fawibe, PO Oluboyo
This report is part of the ongoing highly active antiretroviral therapy (HAART) trial, 167 patients were enlisted, but current analysis was restricted to 107 patients that were about a year old on the programme. The baseline weight, CD4+
cell count and serum albumin of 59 males and 48 females age 15-60 years, were compared with values at 12 months of administration of HAART. Patients mean weight, CD4+
count and serum albumin increased significantly (p-value < 0.05) by 9.7kg, 127.4/uL and 9.1g/L over the enrolment values. Side effects of antiretroviral (ARV) drugs were mild and included; rashes 19.6%, jaundice 7.5% and reactive arthritis 3.5%. Fifty-eight patients (59%) were alive by the end of 1 year, 33 (30%) had died and 11 (10.8%) were lost to follow-up. The risk of death increased 3 times when baseline CD4+
count was less than 116.8/uL (RR= 3.36, 95%CI=1.86– 6.06, P-value = 0.000048). TB/HIV co-infection raised the chance of death twice (RR= 2.33, 95%CI=1.31-4.15, P- value=0.005). In conclusion, the use of triple-drug combination of HAART has led to improved CD4+
cell count and resolution of clinical symptoms in HIV/AIDS patients. These resulted in increased survival.
Key Words: HAART, AIDS, CD4+ cells count and survival.
Afr. J. Clin. Exper. Microbiol. Vol.6(1) 2005:34-39